Private Capital Advisors Inc. bought a new position in bluebird bio Inc (NASDAQ:BLUE) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 2,800 shares of the biotechnology company’s stock, valued at approximately $356,000.

Several other institutional investors also recently made changes to their positions in BLUE. Icon Wealth Partners LLC bought a new stake in shares of bluebird bio during the 1st quarter worth approximately $31,000. Quadrant Capital Group LLC lifted its stake in shares of bluebird bio by 211.5% during the 1st quarter. Quadrant Capital Group LLC now owns 486 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 330 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of bluebird bio by 15.5% during the 4th quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 169 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of bluebird bio by 18.2% during the 1st quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 129 shares during the last quarter. Finally, Oakbrook Investments LLC bought a new stake in shares of bluebird bio during the 1st quarter worth approximately $205,000.

In other news, insider David Davidson sold 7,660 shares of the business’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $129.47, for a total value of $991,740.20. Following the completion of the transaction, the insider now directly owns 38,946 shares of the company’s stock, valued at approximately $5,042,338.62. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jeffrey T. Walsh sold 1,500 shares of the business’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $132.30, for a total value of $198,450.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,820 shares of company stock valued at $2,493,620. Corporate insiders own 3.00% of the company’s stock.

NASDAQ BLUE traded down $2.56 on Monday, reaching $137.18. 7,454 shares of the stock traded hands, compared to its average volume of 501,892. The company has a current ratio of 9.31, a quick ratio of 9.31 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $128.09. The company has a market cap of $7.52 billion, a P/E ratio of -12.83 and a beta of 2.30. bluebird bio Inc has a 12 month low of $87.49 and a 12 month high of $176.55.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.79) by ($0.20). The company had revenue of $12.47 million during the quarter, compared to the consensus estimate of $15.49 million. bluebird bio had a negative return on equity of 34.01% and a negative net margin of 1,184.01%. The company’s revenue was down 21.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.31) earnings per share. Equities analysts anticipate that bluebird bio Inc will post -12.26 EPS for the current year.

A number of equities research analysts recently issued reports on BLUE shares. BidaskClub raised Northrim BanCorp from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. William Blair reissued an “outperform” rating on shares of Activision Blizzard in a research note on Friday, May 3rd. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. BMO Capital Markets raised Bank of America from a “market perform” rating to an “outperform” rating and set a $37.00 price target for the company in a research note on Monday, June 17th. Finally, Wedbush reissued an “outperform” rating and set a $124.00 price target on shares of New Relic in a research note on Wednesday, May 15th. Ten research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $157.39.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Recommended Story: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.